CSTL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

76.40M

-11.48%

-0.344

-207.42%

75.91M

-13.72%

-0.478

-46.89%

81.85M

-5.04%

-0.378

-352%

Estimates Revision

The market is revising Upward the revenue expectations for Castle Biosciences, Inc. (CSTL) for FY2025, with the revenue forecasts being adjusted by 4.92% over the past three months. During the same period, the stock price has changed by 70.45%.

Revenue Estimates for FY2025

Revise Upward

+4.92%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-39.33%

In Past 3 Month

Stock Price

Go Up

+70.45%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

23.56

Averages

34.39

High

41.00

Current: 0.000

Low

23.56

Averages

34.39

High

41.00

Guggenheim

NULL -> Buy

maintain

$30 -> $43

2026-01-05

New

Reason

Guggenheim

Price Target

$30 -> $43

2026-01-05

New

maintain

NULL -> Buy

Reason

Guggenheim raised the firm's price target on Castle Biosciences to $43 from $30 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.

Canaccord

Buy

maintain

$37 -> $50

2025-12-22

Reason

Canaccord

Price Target

$37 -> $50

2025-12-22

maintain

Buy

Reason

Canaccord raised the firm's price target on Castle Biosciences to $50 from $37 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they maintain the highest level of conviction in the risk-reward profile and share price appreciation potential for Castle Biosciences.

BTIG

Mark Massaro

Buy

upgrade

$38 -> $50

2025-12-12

Reason

BTIG

Mark Massaro

Price Target

$38 -> $50

2025-12-12

upgrade

Buy

Reason

BTIG analyst Mark Massaro raised the firm's price target on Castle Biosciences to $50 from $38 and keeps a Buy rating on the shares as part of a broader research note reviewing 2025 for Diagnostics and Tools. The firm is also positive on the stock's risk-reward, adding that at 2.6-times sales, the stock has a best-in-class financial profile, the analyst tells investors in a research note.

Baird

NULL -> Outperform

maintain

$39 -> $41

2025-11-04

Reason

Baird

Price Target

$39 -> $41

2025-11-04

maintain

NULL -> Outperform

Reason

Baird raised the firm's price target on Castle Biosciences to $41 from $39 and keeps an Outperform rating on the shares. The firm updated its model following solid Q3 results and raised revenue outlook.

Scotiabank

Outperform

downgrade

$44 -> $40

2025-05-21

Reason

Scotiabank

Price Target

$44 -> $40

2025-05-21

downgrade

Outperform

Reason

Scotiabank lowered the firm's price target on Castle Biosciences to $40 from $44 and keeps an Outperform rating on the shares. The company raised its full year guidance despite DecisionDx-SCC no longer being reimbursed by Medicare and the discontinuation of IDgenetix, the analyst tells investors. The company remains on track to launch a therapy guidance test for atopic dermatitis by the end of 2025, the firm adds.

Baird

Catherine Ramsey

Buy

Maintains

$36 → $37

2025-02-28

Reason

Baird

Catherine Ramsey

Price Target

$36 → $37

2025-02-28

Maintains

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Castle Biosciences Inc (CSTL.O) is -26.15, compared to its 5-year average forward P/E of -18.00. For a more detailed relative valuation and DCF analysis to assess Castle Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.00

Current PE

-26.15

Overvalued PE

-3.15

Undervalued PE

-32.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.40

Current EV/EBITDA

51.39

Overvalued EV/EBITDA

4.49

Undervalued EV/EBITDA

-33.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.97

Current PS

3.52

Overvalued PS

11.91

Undervalued PS

0.04

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CSTL News & Events

Events Timeline

No data

News

5.0

2025-12-23NASDAQ.COM

AstraZeneca Secures FDA Approval for Enhertu in First-Line Breast Cancer, Triggers $150M Milestone Payment

9.0

2025-12-19NASDAQ.COM

Novo Nordisk Submits NDA for Advanced Obesity Treatment CagriSema

5.0

2025-12-19Globenewswire

Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement

People Also Watch

Frequently Asked Questions

What is Castle Biosciences Inc (CSTL) stock price today?

The current price of CSTL is 39.34 USD — it has decreased -1.38 % in the last trading day.

What is Castle Biosciences Inc (CSTL)'s business?

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

What is the price predicton of CSTL Stock?

What is Castle Biosciences Inc (CSTL)'s revenue for the last quarter?

Castle Biosciences Inc revenue for the last quarter amounts to 83.04M USD, decreased -3.19 % YoY.

What is Castle Biosciences Inc (CSTL)'s earnings per share (EPS) for the last quarter?

Castle Biosciences Inc. EPS for the last quarter amounts to -0.02 USD, decreased -125.00 % YoY.

What changes have occurred in the market's expectations for Castle Biosciences Inc (CSTL)'s fundamentals?

How many employees does Castle Biosciences Inc (CSTL). have?

Castle Biosciences Inc (CSTL) has 761 emplpoyees as of January 10 2026.

What is Castle Biosciences Inc (CSTL) market cap?

Today CSTL has the market capitalization of 1.15B USD.